ArticleFrontiers in endocrinology2025
25-hydroxyvitamin D as a predictor of reduced heart rate variability in elderly patients with diabetes mellitus.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reduced heart rate variability predicts incident diabetic polyneuropathy.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the risk factors for decreased heart rate variability (HRV) in elderly diabetic patients and evaluate the predictive value of 25-hydroxyvitamin D [25-(OH)D]. Methods: A retrospective study was conducted, enrolling 101 elderly diabetic patients admitted to the Department of Geriatric Endocrinology at the First Affiliated Hospital of Anhui Medical University from 2023 to 2024. Patients were divided into two groups based on the standard deviation of all normal RR intervals (SDNN) from 24-hour Holter monitoring: the normal HRV group (180 ms ≥ SDNN ≥ 100 ms) and the decreased HRV group (SDNN < 100 ms). Clinical data collected included age, sex, body mass index (BMI), Diabetic peripheral neuropathy (DPN), Diabetic peripheral vascular disease (DPVD), Diabetic nephropathy (DN), Diabetic retinopathy (DR), as well as laboratory parameters such as fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), creatinine (Cr), glomerular filtration rate (GFR), uric acid (UA), cystatin C (CysC), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), very-low-density lipoprotein cholesterol (VLDL-C), non-HDL-C, 25-(OH)D, 24-hour urinary total protein (24hUTP), 24-hour urinary uric acid (24hUA), microalbuminuria (MAlb), urinary albumin-to-creatinine ratio (UACR), and calculated ratios including TG/HDL-C, UA/HDL-C, and non-HDL-C/HDL-C. Statistical analyses included χ² test, independent Results: Compared with the normal HRV group, the decreased HRV group had significantly lower HDL-C and 25-(OH)D levels but higher prevalence of DN, along with elevated 24hUTP, MAlb, UACR, TG/HDL-C, and UA/HDL-C (all P < 0.05). These factors were identified as independent risk factors for HRV reduction in elderly diabetic patients. Conclusion: This study identified key risk factors for HRV reduction in elderly diabetic patients. Furthermore, 25-(OH)D levels may serve as an early predictive marker for decreased HRV in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.